Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 1-10 of 47
Blood Cancer
Enasidenib for Patients with Clonal Cytopenias of Undetermined Significance
Enasidenib for Patients with Clonal Cytopenias of Undetermined Significance Summary Individuals with cytopenia (low blood cell counts) and clonal hematopoiesis (hee-MA-toh-poy-EE-sis), who do not meet the criteria for a hematologic malignancy, have an entity called clonal cytopenias of undetermined significance (CCUS). These patients have an 82% and 95% chance at 5 years and 10 years, […]
Washington University in St. Louis
Sarcoma
PEMIGIST: Phase II Study of Pemigatinib in SDH-deficient GIST
PEMIGIST: Phase II Study of Pemigatinib in SDH-deficient GIST Summary Gastrointestinal stromal tumors (GISTs) are a group of rare cancers, with an incidence of 4,000 to 6,000 new cases per year in the United States. Approximately 10-15% of adult GISTs and the majority of pediatric GISTs are driven by the loss of the SDH protein […]
Dana-Farber Cancer Institute
Pediatric Blood Cancer
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD Summary: Allogeneic hematopoietic stem cell transplants (stem cell transplant from a donor) [HSCT] are an important treatment for high-risk hematologic (blood) malignancies. However, these transplants can result in graft versus host disease (GVHD) which targets the skin, liver, and GI tract. This occurs in about […]
John Levine, MD, MS
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute
Breast Cancer
Omission of Surgery after Neoadjuvant Chemotherapy in Breast Cancer
Omission of Surgery after Neoadjuvant Chemotherapy in Breast Cancer Summary: There is a potential for a paradigm shift in the way some early-stage breast cancer patients are treated. Currently, every breast cancer patient undergoing curative intent treatment requires surgery. However, for patients that achieved a complete response to pre-operative chemotherapy it may not be necessary. […]
Sachin Jhawar, MD, MSCI
The Ohio State University
Breast Cancer
A Phase II Multi-Center Open-Label Randomized Study of Capecitabine in Combination with Elacestrant versus Capecitabine Alone in Advanced Estrogen Receptor Positive Breast Cancer (CapEla)
A Phase II Multi-Center Open-Label Randomized Study of Capecitabine in Combination with Elacestrant versus Capecitabine Alone in Advanced Estrogen Receptor Positive Breast Cancer (CapEla) Summary: Endocrine therapy and targeted therapy such as CDK4/6 inhibitors and other inhibitors targeting the PI3K-AKT-mTOR pathway are highly effective in metastatic hormone receptor positive (HR+) breast cancer. However, nearly all […]
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Neuroblastoma
NANT2101 STING (Sequential Temozolomide, Irinotecan, NK cells, and GD2 mAb)
NANT2101 STING (Sequential Temozolomide, Irinotecan, NK cells, and GD2 mAb)
Araz Marachelian, MD, MS
Children's Hospital Los Angeles
Breast Cancer
PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC with Residual Disease
PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC with Residual Disease Summary: Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of new breast cancer cases and has been associated with poor clinical outcomes. Recently, neoadjuvant chemo-immunotherapy has been established as the standard of care in patients with stage II/III TNBC and substantially improved […]
Yara Abdou, MD
University of North Carolina
Sarcoma
Phase II study of All-trans retinoic acid and Cemiplimab in Leiomyosarcoma
Phase II study of All-trans retinoic acid and Cemiplimab in Leiomyosarcoma Summary: Soft-tissue sarcomas encompass a group of rare malignant tumors and account for less than 1% of all adult malignancies in the United States. There are an estimated 13,130 new cases per year and approximately 5,350 deaths.
Gabriel Tinoco, MD
The Ohio State University
Breast Cancer
The ARCHER trial (Ablation and Resection for the Consolidation of Oligometastatic HER2+ Breast Cancer)
The ARCHER trial (Ablation and Resection for the Consolidation of Oligometastatic HER2+ Breast Cancer) Summary: In recent years, several highly effective targeted agents have emerged for HER2-positive (HER2+) breast cancer, converting a breast cancer subtype that historically had the worst outcomes to the most favorable in the context of targeted agents. Recent trials have demonstrated […]
Lior Braunstein, MD
Memorial Sloan Kettering Cancer Center
Blood Cancer
A Phase II Trial of Pembrolizumab + GVD with ctDNA-guided Consolidation in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma
A Phase II Trial of Pembrolizumab + GVD with ctDNA-guided Consolidation in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Summary: The current standard of care for relapsed or refractory classic Hodgkin lymphoma (cHL) is salvage chemotherapy followed by autologous stem cell transplant (ASCT), resulting in a cure for over 60% of patients. While ASCT is an […]
Michael Spinner, MD
University of California, San Francisco